This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lind, H. Articles by Zienolddiny, S. Search for Related Content PubMed PubMed Citation Articles by Lind, H. Articles by Zienolddiny, S.

Frequency of TP53 Mutations in Relation to Arg72Pro Genotypes in Non–Small Cell Lung Cancer

¹ Section of Toxicology, Department of Chemical and Biological Working Environment, National Institute of Occupational Health; ² Department of Surgical Oncology, The Norwegian Radium Hospital, Oslo, Norway; and ³ Haukeland University Hospital, Bergen, Norway

Requests for reprints: Shanbeh Zienolddiny, Section of Toxicology, Department of Chemical and Biological Working Environment, National Institute of Occupational Health, P.O. Box 8149 Dep, 0033 Oslo, Norway. Phone: 47-23-19-51-00; Fax: 47-23-19-52-03. E-mail: shan.zienolddiny{at}stami.no

Mutations in the TP53 gene are important events during human lung carcinogenesis. The TP53 gene harbors several polymorphisms, and functional studies have shown that the Arg72Pro polymorphism alters both wild-type and mutant p53 protein activity. Thus, we hypothesized that certain Arg72Pro genotypes may influence the frequency and pattern of somatic mutations in TP53. We therefore examined the status of the Arg72Pro polymorphism and TP53 mutations in 260 non–small-cell lung cancer cases. Here we report a significant trend toward lower frequency of TP53 mutations with increasing number of Pro72 alleles (P = 0.02). Overall, Pro72 allele carriers had significantly lower frequency of TP53 mutations compared with Arg72 homozygotes (P = 0.02). In addition, carriage of the Pro72 variant was related to a lower frequency of mutations affecting the hotspot codon 273. Mutations at codon 273 accounted for 10.6% of the mutations in Arg72 homozygotes and 1.7% of the mutations in Pro72 allele carriers. Our results suggest that the genotype of the Arg72Pro polymorphism may modulate the frequency of TP53 mutations in non–small-cell lung cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(10):2077–81)